Introduction: Individual response to interferon beta (IFN-β) 1a treatment is heterogeneous in
multiple sclerosis (MS). Our objective was to find a connection between serum levels of interleukin
(IL)-10, IL-17 and transforming growth factor beta (TGF-β)1 in MS patients treated with IFN-β in order
to identify the nonresponders (NR).
Material and Methods: We included in the study 32 healthy subjects and 32 MS patients: 10 naive, 10
early treated and 12 late treated with INF-β1a. Serum determination of cytokines and brain MRI were
performed at the beginning of the study, after 6 and 12 months. Rio score was calculated at the end of
Results: MS patients had initially a significant higher level of IL-17 and a lower level of TGF-β1
compared to healthy subjects. IL-17 level in early treated patients was significantly lower compared to
the naive and late treated groups. INF-β1a treatment significantly increased IL-10 and decreased IL-17
levels. Initial low levels of IL-10 were associated with an increase in physical disability. IL-17 levels
positively correlated with the number of relapses and MRI activity. Nine patients were NR to Avonex.
Patients with a Rio score of 3 had higher initial levels of IL-17 and those with a Rio score of 0 had
higher initial levels of IL-10 and TGF-β1.
Conclusion: IFN-β1a decreased IL-17 and increased IL-10 seric levels; IL-17 significantly correlated
with MS activity; TGF-β1 activity is titer-dependent, increased levels were associated with IL-17
inhibition; NR patients to IFN-β1a will have initial high IL-17 and low IL-10 and TGF-β seric levels.